Norepinephrine

Summary

Norepinephrine (CHEMBL1437) is an approved small-molecule vasoconstrictor agent (ATC C01CA03) targeting ADRA1A, ADRA1B, and ADRA1D; indicated across 19 conditions including cardiovascular disorder and hypotensive disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: C01CA03
• Targets: 9 (ADRA1A, ADRA1B, ADRA1D…)
• Indications: 19 conditions
• Clinical trials: 209
• Chemistry: 169.18 Da · C8H11NO3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1437
Name	Norepinephrine
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	439260
ChEBI	CHEBI:18357
ATC	C01CA03
Molecular formula	C8H11NO3
Molecular weight	169.18
InChIKey	SFLSHLFXELFNJZ-QMMMGPOBSA-N

SMILES: C1=CC(=C(C=C1[C@H](CN)O)O)O

IUPAC name: 4-[(1R)-2-amino-1-hydroxyethyl]benzene-1,2-diol

ChEBI definition: The R-enantiomer of noradrenaline.

Pharmacological roles (ChEBI): neurotransmitter, vasoconstrictor agent, α-adrenergic agonist, sympathomimetic agent.

Other ChEBI roles (chemical / environmental): mouse metabolite.

Also known as: (-)-noradrenaline, Levarterenol, Nor adrenalin, Noradrenaline, Norepinefrina, Norepinephrine, NSC-757246, R-norepinephrine, norepinephrine, norepinehprine, (-)-Arterenol, (-)norepinephrine

Parent form; salt/anhydrous children: CHEMBL1356607, CHEMBL1434513, CHEMBL2130595, CHEMBL2311152, CHEMBL3248963, CHEMBL3273169, CHEMBL5087452

Patent coverage: 34,865 distinct patent families (108,675 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 108,612 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
ADRA1A	α1A-adrenoceptor	Full agonist	8.6		P35348
ADRA1B	α1B-adrenoceptor	Full agonist	9.2	0%	P35368
ADRA1D	α1D-adrenoceptor	Full agonist	7.8	0.2%	P25100
ADRA2A	α2A-adrenoceptor	Full agonist	5.3	0.1%	P08913
ADRA2B	α2B-adrenoceptor	Full agonist	6.9	0.2%	P18089
ADRA2C	α2C-adrenoceptor	Full agonist	6.6	0%	P18825
ADRB1	β1-adrenoceptor	Agonist	7.9	0%	P08588
ADRB2	β2-adrenoceptor	Agonist	6.4	0.4%	P07550
ADRB3	β3-adrenoceptor	Full agonist	7.2	0.1%	P13945

Broader ChEMBL bioactivity targets: 43 (assay-derived). Sample: Tyrosyl-DNA phosphodiesterase 1, Microtubule-associated protein tau, Fructose-bisphosphate aldolase, Prelamin-A/C, ATP-dependent DNA helicase Q1, RecQ-like DNA helicase BLM, 4’-phosphopantetheinyl transferase ffp, 15-hydroxyprostaglandin dehydrogenase [NAD(+)], Alpha-2A adrenergic receptor, Adrenergic receptor alpha-1.

Bioactivity

ChEMBL activities: 111 potent at pChembl ≥ 5 of 129 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
ADRA1A	8.92	AC50	1.2	nM	CHEMBL_ACT_25208861
P15823	8.92	EC50	1.2	nM	CHEMBL_ACT_511304
ADRA1A	8.77	AC50	1.7	nM	CHEMBL_ACT_25230083
P19328	8.32	Ki	4.8	nM	CHEMBL_ACT_1300150
P19328	8.32	Ki	4.8	nM	CHEMBL_ACT_592915
ADRA2A	8.28	AC50	5.3	nM	CHEMBL_ACT_25157089
ADRB3	8.26	EC50	5.5	nM	CHEMBL_ACT_2138185
ADRB3	8.2	EC50	6.3	nM	CHEMBL_ACT_2138210
ADRA1A	8.04	EC50	9.1	nM	CHEMBL_ACT_15667125
ADRA1A	8.04	EC50	9.1	nM	CHEMBL_ACT_18235146
LMNA	7.95	Potency	11.2	nM	CHEMBL_ACT_3648276
P23944	7.92	EC50	12.02	nM	CHEMBL_ACT_109220
ADRA2B	7.92	AC50	12	nM	CHEMBL_ACT_25144041
P15823	7.8	IC50	16	nM	CHEMBL_ACT_761087
P19328	7.77	Ki	17	nM	CHEMBL_ACT_522354
P19328	7.7	Ki	20	nM	CHEMBL_ACT_850908
P23944	7.65	Ki	22.39	nM	CHEMBL_ACT_109211
ADRA2A	7.57	AC50	27	nM	CHEMBL_ACT_25221421
P19328	7.52	Ki	30	nM	CHEMBL_ACT_838951
ADRA2A	7.52	Ki	30	nM	CHEMBL_ACT_904389
P19328	7.48	IC50	33	nM	CHEMBL_ACT_1158593
P19328	7.43	Ki	37	nM	CHEMBL_ACT_1158592
P19328	7.43	Ki	37	nM	CHEMBL_ACT_163091
P19328	7.42	Ki	38	nM	CHEMBL_ACT_1003327
P10608	7.28	EC50	52	nM	CHEMBL_ACT_1003331
ADRA2B	7.21	EC50	61.66	nM	CHEMBL_ACT_1837304
ADRA2B	7.21	EC50	61.66	nM	CHEMBL_ACT_1914838
ADRA2B	7.21	EC50	61.66	nM	CHEMBL_ACT_2460025
ADRA2C	7.2	Ki	63	nM	CHEMBL_ACT_766852
ADRA2A	7.18	Ki	66	nM	CHEMBL_ACT_766850

Target pathways

Aggregated over 9 target gene(s): ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3.

Top Reactome pathways

29 total, by targets touching each:

Pathway	Targets	Genes
Signal Transduction	9	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3
Signaling by GPCR	9	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3
Class A/1 (Rhodopsin-like receptors)	9	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3
Amine ligand-binding receptors	9	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3
GPCR downstream signalling	9	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3
Adrenoceptors	9	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3
GPCR ligand binding	9	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3
Hemostasis	3	ADRA2A, ADRA2B, ADRA2C
Adrenaline signalling through Alpha-2 adrenergic receptor	3	ADRA2A, ADRA2B, ADRA2C
Metabolism of proteins	3	ADRA2A, ADRA2C, ADRB2
G alpha (q) signalling events	3	ADRA1A, ADRA1B, ADRA1D
G alpha (12/13) signalling events	3	ADRA1A, ADRA1B, ADRA1D
G alpha (s) signalling events	3	ADRB1, ADRB2, ADRB3
G alpha (i) signalling events	3	ADRA2A, ADRA2B, ADRA2C
G alpha (z) signalling events	3	ADRA2A, ADRA2B, ADRA2C
Platelet activation, signaling and aggregation	3	ADRA2A, ADRA2B, ADRA2C
Platelet Aggregation (Plug Formation)	3	ADRA2A, ADRA2B, ADRA2C
Metabolism	2	ADRA2A, ADRA2C
Integration of energy metabolism	2	ADRA2A, ADRA2C
Adrenaline,noradrenaline inhibits insulin secretion	2	ADRA2A, ADRA2C
Regulation of insulin secretion	2	ADRA2A, ADRA2C
Surfactant metabolism	2	ADRA2A, ADRA2C
Membrane Trafficking	1	ADRB2
Vesicle-mediated transport	1	ADRB2
Deubiquitination	1	ADRB2
Ub-specific processing proteases	1	ADRB2
Post-translational protein modification	1	ADRB2
Cargo recognition for clathrin-mediated endocytosis	1	ADRB2
Clathrin-mediated endocytosis	1	ADRB2

Dominant GO biological processes

GO term	Targets
signal transduction	9
G protein-coupled receptor signaling pathway	9
positive regulation of MAPK cascade	9
adrenergic receptor signaling pathway	8
adenylate cyclase-activating adrenergic receptor signaling pathway	7
cell-cell signaling	5
regulation of vasoconstriction	5
adenylate cyclase-inhibiting adrenergic receptor signaling pathway	5
adenylate cyclase-modulating G protein-coupled receptor signaling pathway	4
adenylate cyclase-activating G protein-coupled receptor signaling pathway	4
regulation of smooth muscle contraction	4
phospholipase C-activating G protein-coupled receptor signaling pathway	3
positive regulation of cytosolic calcium ion concentration	3
neuron-glial cell signaling	3
epidermal growth factor receptor signaling pathway	3

Indications & clinical

Indications

19 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
cardiovascular disorder	4	MONDO:0004995	EFO:0000319
hypotensive disorder	3	MONDO:0005468	EFO:0005251
toxic shock syndrome	3	MONDO:0001881	EFO:0006834
heart disorder	3	MONDO:0005267	EFO:0003777
congenital heart disease	3	MONDO:0005453	EFO:0005207
hepatorenal syndrome	3	MONDO:0001382	MONDO:0001382
syndromic disease	3	MONDO:0002254	MONDO:0002254
stroke disorder	3	MONDO:0005098	EFO:0000712
acute lung injury	2	MONDO:0015796	EFO:0004610
brain injury	2	MONDO:0043510	MONDO:0043510
orthostatic hypotension	1	MONDO:0005469	EFO:0005252
depressive disorder	1	MONDO:0002050	MONDO:0002050
radiodermatitis	1	MONDO:0043771	MONDO:0043771
obesity disorder	0	MONDO:0011122	EFO:0001073

5 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 209.

Phase distribution

Phase	Trials
Not specified	93
PHASE4	58
PHASE3	28
PHASE2	7
EARLY_PHASE1	7
PHASE2/PHASE3	6
PHASE1	6
PHASE1/PHASE2	4

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02118467	PHASE4	RECRUITING	Vasoactive Drugs in Intensive Care Unit
NCT04592744	PHASE4	ENROLLING_BY_INVITATION	Angiotensin 2 for AKI After OLT
NCT04934748	PHASE4	ENROLLING_BY_INVITATION	The GUARDIAN Trial - Vasopressor Sub-Study
NCT06498115	PHASE4	RECRUITING	Norepinephrine on Maternal Hypotension After Combined Lumbar and Epidural Anaesthesia
NCT06746753	PHASE4	NOT_YET_RECRUITING	Mechanistic Assessment of Norepinephrine Therapy vs. Angiotensin-II in Septic Shock
NCT06802224	PHASE4	RECRUITING	The Choice of Vasopressor to Prevent Postoperative Acute Kidney Injury After Major Non-Cardiac Surgery
NCT06934798	PHASE4	RECRUITING	Inotropic Effects of Vasopressin Versus Noradrenaline In Patients With Vasoplegic Syndrome After Cardiac Surgery
NCT07322133	PHASE4	RECRUITING	Dopamine vs. Norepinephrine for Hypotension in Neonates With Pulmonary Hypertension (DONE)
NCT07322419	PHASE4	RECRUITING	Hemodynamics During Cesarean Delivery Under Spinal Anesthesia With Norepinephrine Versus Ephedrine
NCT07379710	PHASE4	NOT_YET_RECRUITING	Norepinephrine With Ephedrine Versus Norepinephrine Alone During Spinal Anesthesia for Cesarean Delivery
NCT07529795	PHASE4	NOT_YET_RECRUITING	Low-dose Norepinephrine Infusion for Prevention of Post-induction Hypotension in Emergency Surgery for Peritonitis
NCT00484133	PHASE4	UNKNOWN	Microcirculation Guided Therapy Versus Standard Treatment of Severe Sepsis
NCT00894621	PHASE4	UNKNOWN	Norepinephrine as Early Vasopressor Therapy in Children Undergoing Mechanical Ventilation
NCT01367743	PHASE4	COMPLETED	Study Comparing the Efficacy and Tolerability of Epinephrine and Norepinephrine in Cardiogenic Shock
NCT01418118	PHASE4	COMPLETED	Assessment of the Effects of Pressors on Graft Blood Flow After Free Tissue Transfer Surgery
NCT01536470	PHASE4	COMPLETED	Intraoperative Noradrenaline to Control Arterial Pressure (INPRESS Study)
NCT02085291	PHASE4	COMPLETED	Effect of Different Strategies for Titrating a High MAP on Microcirculation
NCT02203630	PHASE4	TERMINATED	Phenylephrine Versus Norepinephrine for Septic Shock in Critically Ill Patients
NCT02241083	PHASE4	COMPLETED	The Effect of Norepinephrine and Dopamine on Radial Forearm Free Flap Tissue Oxygen Pressure and Microdialysate Metabolite Measurements
NCT02354833	PHASE4	COMPLETED	Phenylephrine vs. Norepinephrine Infusion After Spinal Anesthesia for Cesarean Delivery
NCT02454348	PHASE4	WITHDRAWN	NOrepinephrine and VasoprEssin Versus Norepinephrine aLone in Critically Ill Patients With Septic Shock
NCT02477501	PHASE4	COMPLETED	Ephedrine vs. Nor Epinephrine Infusion in Preventing Hypotension After Spinal Anesthesia for Cesarean Section
NCT02519699	PHASE4	COMPLETED	Microcirculation After MAP Increase in Septic Shock Patients With Previous Hypertension
NCT02640846	PHASE4	UNKNOWN	Effects of Levosimendan, Milrinone and Norepinephrine on Left and Right Ventricular Function in Septic Shock
NCT02675868	PHASE4	COMPLETED	Effects of Vasopressors on Immune Response
NCT02854787	PHASE4	COMPLETED	Intravenous Bolus of Phenylephrine vs. Norepinephrine in Preventing Hypotension After Spinal Anesthesia
NCT02969239	PHASE4	UNKNOWN	Norepinephrine and Phenylephrine for Maternal Cardiac Output During Spinal Anesthesia for Elective Cesarean Delivery
NCT03163914	PHASE4	COMPLETED	Effect of Vasopressors on Spinal Anaesthesia Induced Hypotension
NCT03234816	PHASE4	COMPLETED	Vasopressor Prophylaxis After Spinal Anesthesia
NCT03248791	PHASE4	UNKNOWN	Vasopressor Infusion in Cesarean Delivery
NCT03328533	PHASE4	COMPLETED	Norepinephrine Versus Phenylephrine Continuous Variable Infusion in Cesarean Delivery
NCT03706755	PHASE4	COMPLETED	Comparison of Two Doses of Norepinephrine in Preventing Hypotension After Spinal Anesthesia
NCT03712111	PHASE4	UNKNOWN	Comparison of Vasopressor Boluses for Management of Hypotension After Spinal Anesthesia
NCT03719625	PHASE4	UNKNOWN	Norepinephrine Versus Ephedrin for Prevention of Post Spinal Anesthesia in Cesarean Section
NCT03792906	PHASE4	COMPLETED	Comparison of Two Norepinephrine Bolus Doses for Management of Post-spinal Hypotension During Cesarean Delivery
NCT03806582	PHASE4	COMPLETED	Effect of a Higher Blood-pressure on Right Ventricular Function
NCT03849508	PHASE4	COMPLETED	Phenylephrine Versus Norepinephrine for Maintenance of Hemodynamic During Cesarean Section Under Spinal Anesthesia
NCT03864094	PHASE4	COMPLETED	Hemodynamics During Induction of General Anesthesia After Prophylactic Ephedrine, Phenylephrine or Norepinephrine.
NCT03872570	PHASE4	UNKNOWN	Effect of Phenylephrine Versus Norepinephrine on Venous Return
NCT03965117	PHASE4	COMPLETED	Effect of Norepinephrine Infusion on Hepatic Blood Flow During Goal-directed Haemodynamic Therapy.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 0 clinical and 1 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

863 molecules share ≥1 primary target. Top 60 by shared-target count:

Molecule	Source	Status	Shared targets
DIHYDROERGOTAMINE	ChEMBL + PubChem	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3
TEGASEROD	ChEMBL + PubChem	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3
ARIPIPRAZOLE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3
EPINEPHRINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3
LABETALOL	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3
CLOZAPINE	ChEMBL + PubChem	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB2, ADRB3
OLANZAPINE	ChEMBL + PubChem	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB2, ADRB3
PRAMIPEXOLE	ChEMBL + PubChem	Phase 4 (approved)	ADRA1A, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3
TAMSULOSIN	ChEMBL + PubChem	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2
BREXPIPRAZOLE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2
BROMOCRIPTINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3
CARVEDILOL	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3
DOXAZOSIN	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB2, ADRB3
EBASTINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB3
HALOPERIDOL	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB2, ADRB3
PHENYLEPHRINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3
THIORIDAZINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3
SPIRAMIDE	ChEMBL	Phase 2	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2
CRIZOTINIB	ChEMBL + PubChem	Phase 4 (approved)	ADRA1A, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3
DESLORATADINE	ChEMBL + PubChem	Phase 4 (approved)	ADRA1A, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3
PROPOXYPHENE	ChEMBL + PubChem	Phase 4 (approved)	ADRA1A, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3
PYRAZINAMIDE	ChEMBL + PubChem	Phase 4 (approved)	ADRA1A, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3
AMITRIPTYLINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2
AMLODIPINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2C, ADRB2, ADRB3
ASTEMIZOLE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB3
AZELASTINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1
CARIPRAZINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1
CLEMASTINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2
CLOMIPRAMINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2
CLOTRIMAZOLE	ChEMBL	Phase 4 (approved)	ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3
DIETHYLSTILBESTROL	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB3
DOBUTAMINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2
DOMPERIDONE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2
ERGOTAMINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2
NAFTOPIDIL	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1
NEFAZODONE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB3
NORTRIPTYLINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2
PIMOZIDE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3
PROCHLORPERAZINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB3
RISPERIDONE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB2
SERTINDOLE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1
SILODOSIN	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB2
VILAZODONE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB2
LISURIDE	ChEMBL	Phase 3	ADRA1A, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2
YOHIMBINE	ChEMBL	Phase 3	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB2
PIZOTYLINE	ChEMBL	Phase 2	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB2
Alogliptin	PubChem	Approved	ADRA1A, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3
Bosentan	PubChem	Approved	ADRA1A, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3
Fidaxomicin	PubChem	Approved	ADRA1A, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3
Tiotropium Bromide Monohydrate	PubChem	Approved	ADRA1A, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3
ACLIDINIUM BROMIDE	ChEMBL + PubChem	Phase 4 (approved)	ADRA1A, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2
Afatinib	ChEMBL + PubChem	Phase 4 (approved)	ADRA1A, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2
CHENODIOL	ChEMBL + PubChem	Phase 4 (approved)	ADRA1A, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2
CLOFARABINE	ChEMBL + PubChem	Phase 4 (approved)	ADRA1A, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2
OLODATEROL	ChEMBL + PubChem	Phase 4 (approved)	ADRA1A, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2
RIFAMPIN	ChEMBL + PubChem	Phase 4 (approved)	ADRA1A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3
ALFUZOSIN	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C
AMOXAPINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB2
APRACLONIDINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C
ASENAPINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C